# Inclusion of sub-group of ASPREE samples into the ADSP

> **NIH NIH U01** · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2021 · $1,092,489

## Abstract

PROJECT SUMMARY
 The ASPREE (ASPirin in Reducing Events in the Elderly) study was a NIH funded, randomized placebo-
controlled trial of daily low-dose aspirin in 19,114 healthy older individuals, completed in 2018 with longitudinal
data. ASPREE recently joined the Alzheimer Disease Sequencing Project (ADSP) and transferred whole
genome sequencing (WGS) data on 2,796 Non-Hispanic White (NHW) samples to the Genomics Center for
Alzheimer Disease (GCAD) to be entered into the ADSP pipeline and incorporated into the Follow-up study of
the ADSP (FUS). This supplement requests funds to process these 2,796 samples through GCAD. In addition,
926 high-risk, older unaffected individuals (these include 115 unaffected ApoE4/4 homozygotes >75 years, 609
unaffected ApoE3/4 carriers >85 years of age, and 202 unaffected individuals >90 years of age) have been
collected as part of the ASPREE study. Of these 926 high-risk individuals, 502 have had WGS performed, and
thus 424 require WGS. All high-risk individuals have been followed longitudinally and have two plasma samples
collected at the participants entry and three years into the study. These individuals are of great interest as they
have the potential to carry protective variants for AD. This proposal requests funds to perform WGS and plasma
biomarker studies on these individuals and be incorporated into the ADSP-FUS dataset.
 The ASPREE program is bi-national and led in Australia by Monash University (PI McNeil), and in the
US by the Berman Center for Outcomes and Clinical Research (PI Murray) and Massachusetts General
Hospital/Harvard Medical School (PI Chan). Primary contact for this supplement proposal will be Dr. Paul Lacaze
at Monash University, Melbourne, Australia. Specific aim 1 is adjudicate and harmonize clinical data from the
two ASPREE datasets to generate high quality inferentially equivalent phenotypes and endophenotypes; Aim 2
is to conduct whole-genome sequencing of 424 high-risk, unaffected samples with longitudinal data ; Aim 3 is to
perform biomarker studies on two separate plasma samples (at enrollment and at 3 year follow-up) on all 926
high-risk ASPREE samples; aim 4 is to collaborate with NIAGADS, GCAD and the Penn Neurodegeneration
Genomics Center (PNGC and HIHG CGESG QC Teams in processing, storage, and delivery of final datasets to
NIAGADS for public data release and aim 5 is to harmonize clinical data from newly acquired and existing FUS
datasets to generate high quality inferentially equivalent phenotypes and endophenotypes.

## Key facts

- **NIH application ID:** 10298048
- **Project number:** 3U01AG066767-02S1
- **Recipient organization:** UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- **Principal Investigator:** MICHAEL L CUCCARO
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,092,489
- **Award type:** 3
- **Project period:** 2020-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10298048

## Citation

> US National Institutes of Health, RePORTER application 10298048, Inclusion of sub-group of ASPREE samples into the ADSP (3U01AG066767-02S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10298048. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*